Agios Pharmaceuticals reports Q2 EPS ($1.93) , consensus ($1.75)

Reports Q2 revenue $12.5M, consensus $9.52M. “With fewer than 40 days to our PDUFA goal date, our commercial team is prepared for the potential U.S. approval of PYRUKYND for thalassemia,” said CEO Brian Goff. “In Q2, we made progress advancing our early- and mid-stage pipeline and remain on track to deliver topline results of the RISE UP Phase 3 trial for PYRUKYND in sickle cell disease by the end of the year. Collectively, our progress reflects our continued focus on delivering innovative medicines with the potential to transform the lives of those affected by rare diseases and deliver long-term shareholder value.”